Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 3, 2017 – Teva announced the FDA approval of Austedo (deutetrabenazine) for the treatment of chorea associated with Huntington’s disease (HD).
Download PDF
Return to publications
